射频消融对比手术切除治疗小肝癌的Meta分析

Efficiency and safety of dezocine in radiofrequency ablation for hepatic carcinoma

AIM: To observe the clinical effects of dezocine in radiofrequency ablation (RFA) for hepatic carcinoma.

METHODS: Forty hepatic carcinoma patients undergoing RFA were randomly divided into two groups: D and F, which were intravenously given dezocine (0.100 mg/kg) and fentanyl (0.001 mg/kg) before the operation started, respectively. After the operator completed the puncture, the two groups were intermittently given intravenous infusion of propofol. Mean arterial pressure (MAP), heart rate (HR), saturation of pulse oximetry (SPO₂) and the dosage of propofol for a single lesion were recorded. The anesthetic effect and adverse events such as glossocoma and respiratory depression during the anesthesia were assessed. Visual analogue scale (VAS) score and adverse events such as nausea and vomiting during the postoperative period were also evaluated.

RESULTS: MAP, HR, and SPO₂ at each time point, the dosage of propofol for a single lesion, anesthetic effect, glossocoma, nausea, vomiting and VAS score at 5 min after the operation showed no statistically significant differences between the two groups (P > 0.05). The rate of respiratory depression was significantly lower in group D (P < 0.05). VAS scores at 30 min and 2 h after the operation were also significantly lower in group D (1.6 ± 1.7 vs 3.3 ± 1.5, 1.2 ± 1.0 vs 3.1 ± 1.2, P < 0.05).

CONCLUSION: During the operation of RFA, dezocine can achieve similar clinical effects to fentanyl with a lower rate of respiratory depression and better postoperative analgesia.